3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
50
Small Cell Lung Carcinoma
23
Breast Neoplasms
17
Sarcoma
16
Carcinoma, Hepatocellular
10
Lung Neoplasms
9
Esophageal Squamous Cell Carcinoma
9
Stomach Neoplasms
8
Neoplasms
8
Triple Negative Breast Neoplasms
7
Ovarian Neoplasms
7
Nasopharyngeal Carcinoma
7
Neoplasm Metastasis
6
Pancreatic Neoplasms
5
NSCLC
5
Colorectal Neoplasms
5
Carcinoma
5
Uterine Cervical Neoplasms
4
Thyroid Neoplasms
4
Pheochromocytoma
4
Esophageal Neoplasms
4
Endometrial Neoplasms
4
Carcinoma, Renal Cell
4
Carcinoma, Ovarian Epithelial
4
Recurrence
3
Paraganglioma
3
Non-squamous Non-small Cell Lung Cancer
3
Glioma
3
Fallopian Tube Neoplasms
3
Cholangiocarcinoma
3
Interventions
Doxorubicin
6
Ifosfamide
5
Radiotherapy
4
pazopanib
3
cediranib
3
atezolizumab
3
Sunitinib
3
selinexor
2
perifosine
2
pembrolizumab
2
Trabectedin
2
Specimen Handling
2
Loperamide
2
Gemcitabine
2
Filgrastim
2
Dacarbazine
2
Cisplatin
2
Biopsy
2
Bevacizumab
2
trifluridine tipiracil drug combination
1
spartalizumab
1
sargramostim
1
romidepsin
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
ixazomib
1
indolepropanol phosphate
1
futibatinib
1
fludarabine
1
cabozantinib
1
brostallicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Sarcoma, Alveolar Soft Part
×
anlotinib
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled